
Cyrus M. Khan, MD, discusses how ibrutinib—a first-generation BTK inhibitor—compares with second-generation BTK inhibitors in CLL.

Your AI-Trained Oncology Knowledge Connection!


Cyrus M. Khan, MD, is an assistant professor of medicine at the Drexel University School of Medicine and assistant director of the Stem Cell Transplant Program at the Allegheny Health Network Cancer Institute in Pittsburgh, Pennsylvania.

Cyrus M. Khan, MD, discusses how ibrutinib—a first-generation BTK inhibitor—compares with second-generation BTK inhibitors in CLL.

Cyrus M. Khan, MD, discusses the key BTK inhibitor updates for the treatment of patients with relapsed/refractory CLL from the 2025 ASCO Annual Meeting.

Cyrus M. Khan, MD, detailed the development of second-generation BTK inhibitors and how they compare with first-generation BTK inhibitors in CLL.

Cyrus M. Khan, MD, discusses how acalabrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

Cyrus M. Khan, MD, discusses how zanubrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

A bone marrow aspirate and biopsy is the single most common procedure that hematologists and oncologists carry out day in and day out throughout their career.

There are many ideas that if followed will not just help you to "do your time" during fellowship, but contribute to the internal medicine residency program.

Obtaining a high-quality bone marrow aspirate and biopsy is very important for the patient—and for you. Following these general guidelines will help you do this successfully.

Cigarette smoking is the leading cause of preventable death in the United States, accounting for approximately 443,000 deaths, or 1 of every 5 deaths each year.

Published: September 13th 2011 | Updated:

Published: April 15th 2012 | Updated:

Published: January 18th 2013 | Updated:

Published: October 31st 2011 | Updated: